NEW YORK, Feb 16 – In its lawsuit against Genomic Solutions, PerkinElmer has alleged that  Genomic Solutions entered a “sham” proposed merger transaction in order to prevent PerkinElmer from being able to execute its call rights to acquire all of Genomic Solutions shares, according to documents PerkinElmer filed in Delaware Chancery Court.

 “GSI and its directors repeatedly have sought to construct and implement a sham transaction for the purpose of frustrating plaintiff’s contract rights,” states a motion obtained by GenomeWeb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.